ZA983497B - Activated protein c formulations. - Google Patents

Activated protein c formulations.

Info

Publication number
ZA983497B
ZA983497B ZA9803497A ZA983497A ZA983497B ZA 983497 B ZA983497 B ZA 983497B ZA 9803497 A ZA9803497 A ZA 9803497A ZA 983497 A ZA983497 A ZA 983497A ZA 983497 B ZA983497 B ZA 983497B
Authority
ZA
South Africa
Prior art keywords
formulations
activated protein
protein
activated
Prior art date
Application number
ZA9803497A
Other languages
English (en)
Inventor
Andrew David Carlson
Theodore Arsay Sheliga
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of ZA983497B publication Critical patent/ZA983497B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4866—Protein C (3.4.21.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6464—Protein C (3.4.21.69)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21069—Protein C activated (3.4.21.69)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Vascular Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
ZA9803497A 1997-04-28 1998-04-24 Activated protein c formulations. ZA983497B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US4525597P 1997-04-28 1997-04-28

Publications (1)

Publication Number Publication Date
ZA983497B true ZA983497B (en) 1999-10-25

Family

ID=21936854

Family Applications (2)

Application Number Title Priority Date Filing Date
ZA9803496A ZA983496B (en) 1997-04-28 1998-04-24 Methods for processing activated protein C.
ZA9803497A ZA983497B (en) 1997-04-28 1998-04-24 Activated protein c formulations.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ZA9803496A ZA983496B (en) 1997-04-28 1998-04-24 Methods for processing activated protein C.

Country Status (35)

Country Link
US (4) US6159468A (de)
EP (2) EP0875252B1 (de)
JP (2) JP4383546B2 (de)
KR (2) KR100450856B1 (de)
CN (2) CN1227025C (de)
AR (2) AR012010A1 (de)
AT (1) ATE285788T1 (de)
AU (2) AU740753C (de)
BR (2) BR9809304B1 (de)
CA (2) CA2288143C (de)
CO (2) CO4950523A1 (de)
CZ (1) CZ298429B6 (de)
DE (1) DE69828330T2 (de)
DK (1) DK0875252T3 (de)
EA (2) EA002149B1 (de)
EG (1) EG23685A (de)
ES (1) ES2234072T3 (de)
HK (1) HK1016472A1 (de)
HU (2) HUP0003401A3 (de)
ID (2) ID23172A (de)
IL (2) IL132325A (de)
IN (2) IN183798B (de)
MY (2) MY118591A (de)
NO (2) NO995134L (de)
NZ (2) NZ337828A (de)
PE (2) PE86299A1 (de)
PL (2) PL195642B1 (de)
PT (1) PT875252E (de)
SI (1) SI0875252T1 (de)
SV (2) SV1998000050A (de)
TR (2) TR199902631T2 (de)
TW (2) TWI242443B (de)
UA (2) UA55448C2 (de)
WO (2) WO1998048822A1 (de)
ZA (2) ZA983496B (de)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6630137B1 (en) * 1997-04-28 2003-10-07 Eli Lilly And Company Activated protein C formulations
EA002149B1 (ru) * 1997-04-28 2001-12-24 Эли Лилли Энд Компани Улучшенные способы приготовления активированного белка с
HUP0001237A3 (en) * 1997-10-20 2002-01-28 Lilly Co Eli Methods for treating vascular disorders
US6815533B1 (en) 1998-07-31 2004-11-09 Eli Lilly And Company Cryogranulation of activated protein C
EP1128842B1 (de) * 1998-11-13 2006-03-15 Eli Lilly And Company Verwendung von menschliche protein c zur herstellung eines arzneimittels zur behandlung von heparininduzierter thrombozytopenie
DE69906568T2 (de) * 1998-11-20 2004-02-12 Eli Lilly And Co., Indianapolis Behandlung von hämorrhagischem virusfieber mit protein c
DK1133314T3 (da) * 1998-11-23 2003-04-14 Lilly Co Eli Protein C til behandling af seglcellesygdom og thalassæmi
WO2000033867A1 (en) * 1998-12-10 2000-06-15 Eli Lilly And Company Method of treating thrombocytopenic purpura and hemolytic uremic syndrome
US6758938B1 (en) * 1999-08-31 2004-07-06 Micron Technology, Inc. Delivery of dissolved ozone
US7204981B2 (en) * 2000-03-28 2007-04-17 Eli Lilly And Company Methods of treating diseases with activated protein C
AU2001262939A1 (en) * 2000-05-24 2001-12-03 Eli Lilly And Company Formulations and use of activated protein c and protein c zymogen for treating hypercoagulable states
ES2309167T3 (es) 2001-02-19 2008-12-16 Merck Patent Gmbh Metodo para identificar epitotes de celulas t y metodo para preparar moleculas con inmunogenicidad reducida.
US7101982B2 (en) * 2001-03-30 2006-09-05 Immunex Corporation Control of ph transitions during chromatography
JP2004535461A (ja) * 2001-07-19 2004-11-25 ディーエムアイ バイオサイエンシズ インコーポレイテッド プロテインｃの不活性化を抑制するための銅キレート剤の使用
CA2462396A1 (en) 2001-09-19 2003-03-27 Oklahoma Medical Research Foundation Treatment of sepsis with tafi
US20030073636A1 (en) * 2001-09-19 2003-04-17 Oklahoma Medical Research Foundation Method of treating diabetes
DE10149030A1 (de) * 2001-10-05 2003-04-10 Viscum Ag Stabile galenische gefriergetrocknete Arzneimittelzubereitung von rViscumin
KR20040040489A (ko) 2001-10-15 2004-05-12 카이론 코포레이션 조직 인자 경로 억제제（ｔｆｐｉ）의 저용량 투여에 의한패혈증의 치료
ATE428439T1 (de) 2001-12-21 2009-05-15 Novo Nordisk Healthcare Ag Flüssige zusammensetzung aus faktor vii polypeptiden
EP1485121A4 (de) * 2002-03-08 2007-11-07 Lilly Co Eli Aktivierte protein-c-formulierungen
PL207018B1 (pl) 2002-06-21 2010-10-29 Novo Nordisk Helth Care Ag Kompozycja farmaceutyczna, sposób przygotowania stabilnego polipeptydu czynnika VII i zastosowanie polipeptydu czynnika VII
AU2003285075B2 (en) * 2002-10-29 2009-10-29 Durect Corporation Stabilized, solid-state polypeptide particles
US20070142272A1 (en) * 2003-01-24 2007-06-21 Zlokovic Berislav V Neuroprotective activity of activated protein c independent of its anticoagulant activity
US7897734B2 (en) 2003-03-26 2011-03-01 Novo Nordisk Healthcare Ag Method for the production of proteins
ES2382157T3 (es) * 2003-06-25 2012-06-05 Novo Nordisk Health Care Ag Composición líquida de polipépttidos del factor VII
SG150552A1 (en) * 2004-03-17 2009-03-30 Chiron Corp Treatment of severe community-acquired pneumonia by administration of tissue factor pathway inhibitor (tfpi)
WO2006014839A2 (en) * 2004-07-23 2006-02-09 The University Of Rochester Activated protein c inhibits undesirable effects of plasminogen activator in the brain
WO2006136033A1 (en) * 2005-06-23 2006-12-28 The University Of British Columbia Coagulation factor iii polymorphisms associated with prediction of subject outcome and response to therapy
ES2386972T3 (es) * 2006-05-31 2012-09-10 Genzyme Corporation Uso de polisacáridos para la estimulación de la actividad enzimática
EP2041338A4 (de) * 2006-06-09 2009-09-30 Univ British Columbia Interferon-gamma-polymorphismen als indikatoren des patientenergebnisses bei schwerkranken patienten
EP2117514B1 (de) * 2007-03-05 2011-06-15 Cadila Healthcare Limited Zusammensetzungen mit peg-interferon-alpha-konjugaten und raffinose als kryoschutzmittel
EP2527364A1 (de) 2007-03-29 2012-11-28 Abbott Laboratories Kristalline Antikörper gegen menschliches IL-12
US8883146B2 (en) 2007-11-30 2014-11-11 Abbvie Inc. Protein formulations and methods of making same
TWI661833B (zh) * 2007-11-30 2019-06-11 百慕達商艾伯維生物技術有限責任公司 蛋白質調配物及製造其之方法
EP2242875A4 (de) * 2008-01-15 2012-04-04 Univ British Columbia Protein-c-rs2069915 als reaktionsprädiktor für überlebensrate und verabreichung einer aktivierten protein-c- oder protein-c-ähnlichen verbindung
RU2011126338A (ru) * 2008-11-28 2013-01-10 Эбботт Лэборетриз Стабильные композиции антител и способы их стабилизации
WO2012068519A2 (en) 2010-11-19 2012-05-24 Sirius Genomics Inc. Markers associated with response to activated protein c administration, and uses thereof
WO2012149197A2 (en) 2011-04-27 2012-11-01 Abbott Laboratories Methods for controlling the galactosylation profile of recombinantly-expressed proteins
EP2834635A4 (de) 2012-04-03 2015-09-02 Smiths Medical Asd Inc Zusammensetzungen mit einem heparinakkumulationsmittel und verfahren dafür
WO2013158279A1 (en) 2012-04-20 2013-10-24 Abbvie Inc. Protein purification methods to reduce acidic species
WO2013158273A1 (en) 2012-04-20 2013-10-24 Abbvie Inc. Methods to modulate c-terminal lysine variant distribution
US9067990B2 (en) 2013-03-14 2015-06-30 Abbvie, Inc. Protein purification using displacement chromatography
US9249182B2 (en) 2012-05-24 2016-02-02 Abbvie, Inc. Purification of antibodies using hydrophobic interaction chromatography
CN104394883B (zh) 2012-07-04 2017-05-31 悉尼大学 炎性皮肤病症的治疗
US9512214B2 (en) 2012-09-02 2016-12-06 Abbvie, Inc. Methods to control protein heterogeneity
US9206390B2 (en) 2012-09-02 2015-12-08 Abbvie, Inc. Methods to control protein heterogeneity
WO2014143205A1 (en) 2013-03-12 2014-09-18 Abbvie Inc. Human antibodies that bind human tnf-alpha and methods of preparing the same
WO2014151878A2 (en) 2013-03-14 2014-09-25 Abbvie Inc. Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosacharides
US8921526B2 (en) 2013-03-14 2014-12-30 Abbvie, Inc. Mutated anti-TNFα antibodies and methods of their use
US9017687B1 (en) 2013-10-18 2015-04-28 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same using displacement chromatography
WO2015051293A2 (en) 2013-10-04 2015-04-09 Abbvie, Inc. Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins
US9085618B2 (en) 2013-10-18 2015-07-21 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same
US8946395B1 (en) 2013-10-18 2015-02-03 Abbvie Inc. Purification of proteins using hydrophobic interaction chromatography
US9181337B2 (en) 2013-10-18 2015-11-10 Abbvie, Inc. Modulated lysine variant species compositions and methods for producing and using the same
WO2015073884A2 (en) 2013-11-15 2015-05-21 Abbvie, Inc. Glycoengineered binding protein compositions
CA2946028C (en) 2014-04-16 2022-10-11 Zz Biotech Llc Treatment of abnormal cutaneous scarring
US11058750B2 (en) 2015-12-03 2021-07-13 Mor Research Applications Ltd. Compositions and methods for treatment of ocular diseases
PL3463308T3 (pl) * 2016-06-01 2022-03-14 Servier IP UK Limited Preparaty poli(tlenku alkilenu)-asparaginazy oraz sposoby ich wytwarzania i zastosowania
CN108159399B (zh) * 2017-12-29 2020-07-24 华中科技大学同济医学院附属同济医院 一种凝血蛋白酶aPC在防治糖尿病心肌病药物中的应用
WO2023119230A1 (en) 2021-12-22 2023-06-29 L'oreal Coagulation pathway and nicotinamide-adenine dinucleotide pathway modulating compositions and methods of their use

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4775624A (en) * 1985-02-08 1988-10-04 Eli Lilly And Company Vectors and compounds for expression of human protein C
US4849403A (en) * 1985-05-29 1989-07-18 Pentapharm Ag Protein C activator, methods of preparation and use thereof
US5516650A (en) 1985-06-27 1996-05-14 Zymogenetics, Inc. Production of activated protein C
AT399095B (de) * 1986-03-27 1995-03-27 Vukovich Thomas Dr Verfahren zur auftrennung von proteinen mittels gradientenelution und vorrichtung zur durchführung des verfahrens
US5175087A (en) * 1987-07-06 1992-12-29 Biopool International, Inc. Method of performing tissue plasminogen activator assay
CA1329760C (en) * 1987-10-29 1994-05-24 Ted C. K. Lee Plasma and recombinant protein formulations in high ionic strength media
US4877608A (en) * 1987-11-09 1989-10-31 Rorer Pharmaceutical Corporation Pharmaceutical plasma protein formulations in low ionic strength media
US4992373A (en) * 1987-12-04 1991-02-12 Eli Lilly And Company Vectors and compounds for direct expression of activated human protein C
JP2739050B2 (ja) * 1988-01-28 1998-04-08 ヘキスト薬品工業株式会社 抗血液凝固剤
JPH01226900A (ja) * 1988-03-08 1989-09-11 Green Cross Corp:The プロテインｃの精製方法
DE3823519A1 (de) * 1988-07-12 1990-01-18 Basf Ag Verfahren zur reinigung von aktiviertem protein c
US4981952A (en) * 1988-10-04 1991-01-01 Eli Lilly And Company Method for the purification of vitamin K-dependent proteins
US5093117A (en) * 1989-01-24 1992-03-03 Baxter International Inc. Compositions and method for the treatment or prophylaxis of sepsis or septic shock
JPH05506354A (ja) * 1990-02-09 1993-09-22 ザイモジェネティクス，インコーポレイティド 端が切り取られた軽鎖を有する活性プロテインｃ
IL97312A (en) * 1990-02-23 1999-01-26 Lilly Co Eli A method of generating a polypeptide in an eukaryotic vector AND recombinant surrogate cell containing an enhanced transcriptional control unit based on the primary late adenovirus coefficient
US5040862A (en) 1990-05-07 1991-08-20 Corning Incorporated Method of trimming optical power
AT402262B (de) * 1991-06-20 1997-03-25 Immuno Ag Arzneimittel enthaltend aktiviertes protein c
US5413732A (en) * 1991-08-19 1995-05-09 Abaxis, Inc. Reagent compositions for analytical testing
MY110664A (en) 1992-05-21 1999-01-30 Lilly Co Eli Protein c derivatives
DE4234295A1 (de) * 1992-10-12 1994-04-14 Thomae Gmbh Dr K Carbonsäurederivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
US5395923A (en) * 1993-02-23 1995-03-07 Haemacure-Biotech, Inc. Process for the obtention of a biological adhesive made of concentrated coagulation factors by "salting-out"
JP3043558B2 (ja) * 1993-10-29 2000-05-22 財団法人化学及血清療法研究所 ヒト活性化プロテインｃ調製物及びその製法
JP2886061B2 (ja) * 1993-10-29 1999-04-26 財団法人化学及血清療法研究所 プロテインｃもしくは活性化プロテインｃの安定化方法及び安定化組成物
JPH07165605A (ja) * 1993-12-16 1995-06-27 Teijin Ltd 活性化プロテインｃバイアル
NZ270271A (en) * 1994-01-05 1996-07-26 Lilly Co Eli Minimizing protein c degradation
JPH08301786A (ja) * 1995-05-11 1996-11-19 Mochida Pharmaceut Co Ltd 吸収性骨疾患予防・治療剤
WO1997020043A1 (en) 1995-11-30 1997-06-05 Zymogenetics, Inc. Protein c production in transgenic animals
EA002149B1 (ru) 1997-04-28 2001-12-24 Эли Лилли Энд Компани Улучшенные способы приготовления активированного белка с
HUP0001237A3 (en) 1997-10-20 2002-01-28 Lilly Co Eli Methods for treating vascular disorders

Also Published As

Publication number Publication date
PE84799A1 (es) 1999-09-16
NZ337828A (en) 2001-06-29
HK1016472A1 (en) 1999-11-05
PE86299A1 (es) 1999-09-17
HU224826B1 (en) 2006-02-28
BR9809292A (pt) 2000-07-04
CN1227025C (zh) 2005-11-16
BR9809304A (pt) 2000-10-17
JP4383547B2 (ja) 2009-12-16
UA55448C2 (uk) 2003-04-15
ES2234072T3 (es) 2005-06-16
JP2001524111A (ja) 2001-11-27
IL132325A0 (en) 2001-03-19
PL336420A1 (en) 2000-06-19
MY120984A (en) 2005-12-30
IL132325A (en) 2005-07-25
EP0875252A3 (de) 2000-07-26
WO1998048822A1 (en) 1998-11-05
NZ500346A (en) 2001-08-31
PT875252E (pt) 2005-03-31
CN1261280A (zh) 2000-07-26
BR9809304B1 (pt) 2011-02-08
AR012010A1 (es) 2000-09-13
EP0875563A2 (de) 1998-11-04
EA199900979A1 (ru) 2000-06-26
AU740753C (en) 2002-10-10
AU7161898A (en) 1998-11-24
SV1998000051A (es) 1998-12-11
HUP0003401A2 (hu) 2001-02-28
DK0875252T3 (da) 2005-04-25
TW585871B (en) 2004-05-01
JP4383546B2 (ja) 2009-12-16
CA2288143A1 (en) 1998-11-05
PL195642B1 (pl) 2007-10-31
KR100450856B1 (ko) 2004-10-02
DE69828330D1 (de) 2005-02-03
EA004881B1 (ru) 2004-08-26
CN1235638C (zh) 2006-01-11
EP0875252B1 (de) 2004-12-29
DE69828330T2 (de) 2005-10-13
AU7258998A (en) 1998-11-24
NO995198D0 (no) 1999-10-25
KR20010020242A (ko) 2001-03-15
EG23685A (en) 2007-05-09
CA2287267C (en) 2006-08-15
US6159468A (en) 2000-12-12
US6436397B1 (en) 2002-08-20
JP2001527543A (ja) 2001-12-25
CO4950523A1 (es) 2000-09-01
NO995134D0 (no) 1999-10-21
US6162629A (en) 2000-12-19
WO1998048818A1 (en) 1998-11-05
TR199902529T2 (xx) 2000-02-21
ID22933A (id) 1999-12-16
CN1254284A (zh) 2000-05-24
CA2288143C (en) 2012-08-21
NO995134L (no) 1999-12-21
EA002149B1 (ru) 2001-12-24
PL336889A1 (en) 2000-07-17
EP0875563A3 (de) 2000-08-02
CZ298429B6 (cs) 2007-10-03
UA73071C2 (en) 2005-06-15
ID23172A (id) 2000-03-23
KR20010020325A (ko) 2001-03-15
NO995198L (no) 1999-10-25
AR015598A1 (es) 2001-05-16
EA199900980A1 (ru) 2000-04-24
IN187157B (de) 2002-02-16
SI0875252T1 (en) 2005-06-30
CZ381099A3 (cs) 2000-03-15
ATE285788T1 (de) 2005-01-15
TR199902631T2 (xx) 2000-01-21
US6395270B1 (en) 2002-05-28
SV1998000050A (es) 1999-01-13
CO4940438A1 (es) 2000-07-24
ZA983496B (en) 1999-10-25
MY118591A (en) 2004-12-31
AU740753B2 (en) 2001-11-15
PL195090B1 (pl) 2007-08-31
HUP0100284A3 (en) 2003-08-28
TWI242443B (en) 2005-11-01
CA2287267A1 (en) 1998-11-05
IL132502A0 (en) 2001-03-19
EP0875252A2 (de) 1998-11-04
AU743531B2 (en) 2002-01-31
IN183798B (de) 2000-04-15
HUP0003401A3 (en) 2003-01-28
KR100564189B1 (ko) 2006-03-27
HUP0100284A2 (hu) 2001-06-28

Similar Documents

Publication Publication Date Title
ZA983497B (en) Activated protein c formulations.
ZA987844B (en) Therapeutic combinations.
ZA9811848B (en) Vaccine.
ZA984969B (en) Vaccine.
ZA988789B (en) Vaccine.
EP1113799A4 (de) Proteinformulierung
ZA982253B (en) Therapeutic compositions.
ZA966075B (en) Protein formulation.
HK1027957A1 (en) Pharmaceutical composition.
HK1016976A1 (en) Resorcinyl-triazine.
ZA981029B (en) Pharmaceutical agents.
ZA9811504B (en) Novel pharmaceutical.
ZA9811506B (en) Novel pharmaceutical.
ZA989680B (en) Pharmaceutical composition.
ZA9811505B (en) Novel pharmaceutical.
GB9719879D0 (en) Protein
GB9703681D0 (en) Protein complemention
EP1018551A4 (de) Megsin-protein
ZA987392B (en) Pharmaceutical composition.
HK1017834A1 (en) Bodyshaper.
ZA983705B (en) Pregnan-3-ol-20-ones.
GB9715064D0 (en) Protein expression
GB9720784D0 (en) Protein
ZA982558B (en) Novel Pharmaceutical.
ZA981309B (en) 4-aminoalkoxy-1H-benzoimidazoles.